WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Alnylam, Inceptive ink AI deal potentially worth $2B — Warptech Lab News

Storia in 5 fonti

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

Raccontata da

morningstar.com

biopharmadive.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 mesi fa

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

Timeline cronologica

mercoledì 3 giugno 2026·morningstar.com
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
mercoledì 3 giugno 2026·statnews.com
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.

3 mesi fa

Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Alnylam Pharmaceuticals (

Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as analysts maintain bullish price targets.

Leggi questa versione → originale

morningstar.com3 mesi fa

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Leggi questa versione → originale

endpoints.news3 mesi fa

Alnylam signs its first AI discovery deal with RNA specialist Inceptive

Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts.

Leggi questa versione → originale

statnews.com3 mesi fa

Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics

Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.

Leggi questa versione → originale

mercoledì 3 giugno 2026·

endpoints.news

Alnylam signs its first AI discovery deal with RNA specialist Inceptive

Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts.

giovedì 4 giugno 2026·

biopharmadive.com

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

giovedì 4 giugno 2026·

statnews.com

AI titans push Congress for DNA safeguards

Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout

giovedì 4 giugno 2026·

benzinga.com

Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Alnylam Pharmaceuticals (

Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as analysts maintain bullish price targets.

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com